key: cord-0688766-h5qrmnca
authors: Esposito, Cinzia; Johansson, Catrine; Di Micco, Simone
title: Editorial: Novel Strategies in Drug Development Against Multifactorial Diseases
date: 2022-01-24
journal: Front Chem
DOI: 10.3389/fchem.2022.838063
sha: a1ab3f1aca708fd3a414a26da7eab8f12bd8029d
doc_id: 688766
cord_uid: h5qrmnca

nan

eicosanoid and glutathione (MAPEG) metabolism superfamily inhibitors, to target the prostaglandin pathway at multiple macromolecular levels for a more effective and safer therapy.

Zhang et al. applied bioinfomatic approaches on selected datasets acquired from the Gene Expression Omnibus (GEO) database to identify novel functional pathways, and diagnostic/ prognostic biomarkers implicated in the pathogenesis of systemic juvenile idiopathic arthritis (sJIA), with as yet unmet medical need. The authors identified six hub genes and specifically suggested ARG1 and PGLYRP1 as potential biomarkers for the early diagnosis of sJIA. Furthermore, Zhang et al. revealed the contribution of the MAPK pathway and immune components such as platelets in the pathogenesis of sJIA paving the way for novel potential molecular targets for sJIA treatment.

Anthwal et al. surveyed the synthetic strategy to obtain 1, 3, 4 thiadiazole-based compounds endowed with different biological activities, such as anti-cancer, anti-viral, anti-diabetic properties. As the 1, 3, 4 thiadiazole could be considered a privileged structure (Di Micco et al., 2016) , the authors suggested that it is suitable to develop anticonvulsant compounds.

The collected contributions provide different perspectives to develop multitarget compounds. This approach potentially represents an opportunity to obtain safer therapeutical treatment and to overcome drug resistance.

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

This research was supported in part by the projects: Fase 2, studio multicentrico aperto per determinare la sicurezza, tollerabilità ed efficacia della larazotide acetato per l'uso urgente in pazienti anziani a rischio per la prevenzione di danno acuto polmonare (ali) e la sindrome da distress respiratorio acuto (ards) associate a infezione da COVID-19-CUP G58D20000240002-SURF 20004BP000000011; Fighting Cancer Resistance: Multidisciplinary Integrated Platform for a Technological Innovative Approach to Oncotherapies (Campania Oncotherapies).

Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling

3-Dihydrobenzofuran Privileged Structures as New Bioinspired lead Compounds for the Design of mPGES-1 Inhibitors

Discovery of New Potent Molecular Entities Able to Inhibit mPGES-1

Discovery of New erbB4 Inhibitors: Repositioning an Orphan Chemical Library by Inverse Virtual Screening

Virtual Fragment Screening Identification of a Quinoline-5,8-Dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor

The Therapeutic Use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases

The authors thank all the contributors, reviewers, handling editors, and the editorial officials of Frontiers in Chemistry.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.